Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement from ...

Albert Bourla, who four years ago led Pfizer through its scientific and financial triumph during the covid-19 pandemic, is suddenly facing a new challenge from a large shareholder frustrated over the ...

As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials.

Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio. After producing record revenue thanks to its work in this area, once the pandemic started receding, sales from ...

Pfizer's best-selling medicines include older products, such as the anticoagulant Eliquis and the cancer drug Ibrance. The healthcare giant's lineup also still features Comirnaty and Paxlovid, its ...

LONDON (Reuters) -Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer. The drugmaker will ...